Researchers described EVG7, a novel glycopeptide antibiotic that prevents Clostridioides difficile recurrence while selectively sparing key commensal gut species. Preclinical data indicate the compound clears pathogenic C. difficile without broadly disrupting microbiota taxa associated with colonization resistance, addressing a key driver of CDI relapse. If validated in clinical trials, EVG7 could reshape treatment algorithms by reducing recurrent infection and the need for fecal microbiota interventions.